{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001620463","name":"LeonaBio, Inc.","summary":"LeonaBio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for treatment-resistant metastatic breast cancer and ALS. Its lead candidates are lasofoxifene, a SERM in-licensed in December 2025 for ESR1-mutated metastatic breast cancer currently in a Phase 3 trial (ELAINE-3), and ATH-1105, a small-molecule HGF system modulator that completed Phase 1 and is Phase 2-ready for ALS treatment.","people":[],"products":[{"name":"Lasofoxifene","type":"platform","description":"Orally bioavailable selective estrogen receptor modulator (SERM) targeting ESR1-mutated ER+/HER2- metastatic breast cancer, in ongoing Phase 3 trial (ELAINE-3) in combination with abemaciclib."},{"name":"ATH-1105","type":"platform","description":"Orally available, brain-penetrant small-molecule positive modulator of the neurotrophic HGF system; Phase 1 completed, Phase 2-ready for ALS treatment."},{"name":"ATH-1020","type":"platform","description":"Early-stage drug candidate targeting the neurotrophic HGF system for potential treatment of multiple neurological diseases."}],"partnerships":[{"partner_name":"Ligand Pharmaceuticals","partnership_type":"licensing","description":"LeonaBio in-licensed lasofoxifene globally (excluding Asia and certain Middle East countries) from Ligand via Sermonix Pharmaceuticals arrangement in December 2025.","start_date":null},{"partner_name":"Sermonix Pharmaceuticals, Inc.","partnership_type":"licensing","description":"Sermonix previously in-licensed lasofoxifene from Ligand and conducted ELAINE Phase 2/3 trials; LeonaBio acquired global rights from Sermonix in December 2025.","start_date":null},{"partner_name":"Duke University","partnership_type":"licensing","description":"Sermonix in-licensed intellectual property related to ESR1 mutations from Duke University in 2016, supporting lasofoxifene's breast cancer IP position.","start_date":null},{"partner_name":"Pfizer Inc.","partnership_type":"development","description":"Pfizer originally co-developed lasofoxifene with Ligand and conducted extensive clinical trials; returned global rights to Ligand in 2011.","start_date":null}],"affiliations":[],"origin":{"leaf":"c492b4240a3dd133828598872310b9aefed4fed92a9c0e53cc04036c2eef2fdb","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f3807d00a384436408f641082f7dfc50667b324b28cf14bc35f02f7512d6969f","parent":"5d990ae9012af7f7b52f5e5d004a9a94078c8957e846dfbe7600629e656c7b06","source":"0001193125-26-134565","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":37,"hourly_limit":500,"remaining":463,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}